Full Press Release Details
SLIDE PRESENTATION.
PALI
SLIDE PRESENTATION
Key Takeaway: SLIDE PRESENTATION
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+50%
120-day peak, hindsight
Typical move
6.1%
average across 7 past catalysts
Cash runway
~49 mo
Minimal dilution risk
Lead asset
PALI-2108
Phase 1 · Fibrostenotic Crohn's Disease